| 16.985 0.265 (1.58%) | 12-05 10:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.79 | 1-year : | 23.12 |
| Resists | First : | 16.95 | Second : | 19.79 |
| Pivot price | 14.34  |
|||
| Supports | First : | 12.43 | Second : | 9.64 |
| MAs | MA(5) : | 15.22 |
MA(20) : | 13.64 |
| MA(100) : | 12.35 |
MA(250) : | 0 | |
| MACD | MACD : | 0.9 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 94.5 |
D(3) : | 85.3 |
| RSI | RSI(14): 71.8 |
|||
| 52-week | High : | 16.95 | Low : | 3.91 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EYPT ] has closed above the upper band by 1.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 97.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.97 - 17.03 | 17.03 - 17.11 |
| Low: | 14.25 - 14.31 | 14.31 - 14.38 |
| Close: | 16.59 - 16.7 | 16.7 - 16.83 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Sun, 30 Nov 2025
XTX Topco Ltd Acquires 94,210 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Fri, 07 Nov 2025
EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Mon, 03 Nov 2025
EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals
Wed, 29 Oct 2025
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 - EyePoint Pharmaceuticals
Tue, 14 Oct 2025
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema - EyePoint Pharmaceuticals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 6.192e+007 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 8,130 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1625e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 420.8 % |
| Return on Equity (ttm) | -49.4 % |
| Qtrly Rev. Growth | 4.234e+007 % |
| Gross Profit (p.s.) | -53.73 |
| Sales Per Share | -58.13 |
| EBITDA (p.s.) | -9.55148e+007 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -211 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.3 |
| Price to Cash Flow | 9.93 |
| Dividend | 0 |
| Forward Dividend | 8.63e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|